Clinical trial
The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen…
NCT00459186 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00459186 |
|---|---|
| Title | The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer |
| Official title | A Phase I/II Study of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Novartis Industry Massachusetts General Hospital Beth Israel Deaconess Medical Center Oregon Health and Science University |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic, Androgen Independent Prostate Cancer, Prostate Cancer |
| Intervention type | Drug |
| Interventions | RAD001, Docetaxel, Prednisone |
| Enrollment | 19 |
| Start date | Nov 1, 2005 |
| Primary completion | Dec 1, 2012 |
| Completion | Dec 1, 2012 |
| First posted | Apr 11, 2007 |
| Last update posted | May 16, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: